Should this drug prove efficacious and safe in long-term phase 3 studies (or, perhaps even now), it should gain regulatory marketing approval from FDA. But even with that, which Parkinson’s therapy would you wish for a close relative, one that requires periodic (or even just-once) brain surgery, or a daily pill that while taken provides continuing suppression of symptoms (the Anavex outcome)?